Skip to main content
Back
Watch Compare

Cardiff Oncology, Inc.

Data quality: 100%
CRDF
Nasdaq Manufacturing Chemicals
$1.58
▼ $0.09 (-5.39%)
Mkt Cap: 114.85 M
Price
$1.68
Mkt Cap
114.85 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue grew 13.37% annually over 5 years — strong growth
Negative free cash flow of -37.97 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 26.55%
Capital efficient — spends only 7.42% of revenue on capex

Growth

Revenue Growth (5Y)
13.37%
Above sector avg (1.82%)
Revenue (1Y)-13.18%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-85.39%
Below sector avg (-53.47%)
ROIC-71.53%
Net Margin-7732.04%
Op. Margin-8256.32%

Safety

Debt / Equity
N/A
Current Ratio4.20
Interest CoverageN/A

Valuation

PE (TTM)
-2.50
Below sector avg (-1.48)
P/B Ratio2.35
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -2.5 -1.5
P/B 2.4 1.6
ROE % -85.4 -53.5
Net Margin % -7732.0 -41.5
Rev Growth 5Y % 13.4 1.8
D/E — 0.3

Analyst Price Target

8 analysts
Buy
Current
$1.58
+390.5%
Target
$7.75
$2.00
$9.25
$12.00
Forecast
Forward P/E -2.26
Forward EPS -$0.70
Est. Revenue 246,430.0

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$0.70
-$0.83 – -$0.59
 246,430.0 4
FY2026 -$0.52
-$0.67 – -$0.37
 338,890.0 5

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.20 -$0.11 +44.1%
Q32025 -$0.21 -$0.17 +18.4%
Q22025 -$0.20 -$0.21 -6.8%
Q12025 -$0.19 -$0.20 -7.5%

ETFs Holding This Stock

IRSIX IRSIX
0.01% weight
IIRSX IIRSX
0.01% weight
IRCIX IRCIX
0.01% weight
VVICX VVICX
0.01% weight
IRSSX IRSSX
0.01% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -13.18% Revenue Growth (3Y) 10.23%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 13.37% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 593,000.0 Net Income (TTM) -45.85 M
ROE -85.39% ROA -65.73%
Gross Margin N/A Operating Margin -8256.32%
Net Margin -7732.04% Free Cash Flow (TTM) -37.97 M
ROIC -71.53% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4.20
Interest Coverage N/A Asset Turnover 0.01
Working Capital 47.10 M Tangible Book Value 48.79 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.50 Forward P/E N/A
P/B Ratio 2.35 P/S Ratio 193.68
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -33.06%
Market Cap 114.85 M Enterprise Value 104.72 M
Per Share
EPS (Diluted TTM) -0.69 Revenue / Share 0.01
FCF / Share -0.56 OCF / Share -0.55
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 7.42% FCF Conversion 82.81%
SBC-Adj. FCF -43.65 M Growth Momentum -26.55

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 593,000.0 683,000.0 488,000.0 386,000.0 359,000.0
Net Income -45.85 M -45.43 M -41.44 M -38.70 M -28.29 M
EPS (Diluted) -0.69 -0.95 -0.93 -0.89 -0.73
Gross Profit — — — — —
Operating Income -48.96 M -48.65 M -45.41 M -39.90 M -28.86 M
EBITDA — — — — —
R&D Expenses — — — 27.10 M 17.40 M
SG&A Expenses 14.22 M 12.48 M 13.04 M 13.18 M 11.84 M
D&A 364,000.0 404,000.0 398,000.0 236,000.0 451,000.0
Interest Expense — — — — 0.0
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 61.88 M 97.19 M 81.64 M 116.19 M 149.54 M
Total Liabilities 16.50 M 14.24 M 11.90 M 9.85 M 9.13 M
Shareholders' Equity 45.39 M 82.95 M 69.74 M 106.34 M 140.42 M
Total Debt — — — — —
Cash & Equivalents 17.47 M 51.47 M 21.66 M 16.35 M 11.94 M
Current Assets 60.13 M 95.05 M 77.41 M 111.28 M 146.13 M
Current Liabilities 16.39 M 13.43 M 10.44 M 7.81 M 6.56 M